Do SGLT2is Improve End-of-Life Care in Adults with Advanced Heart Failure?

AbstractSodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) improve quality of life, functional capacity, and survival, and reduce hospitalization in adults with heart failure (HF). However, most controlled trials to date have enrolled few adults with advanced HF and multiple chronic illnesses. Despite favorable evidence in adults with HF, the safety and effectiveness of SGLT2 inhibitors on patient-centered outcomes in adults with advanced HF and multiple chronic illnesses remain unknown. This Tomorrow's Trial reviews the existing evidence and proposes a trial to address the question, "Do SGLT2 inhibitors improve end-of-life care in adults with advanced heart failure?"